News

The product, also known as Vigil, is being evaluated in the ongoing randomized, placebo-controlled phase 2b VITAL clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The hematology-oncology and BMT cell therapy fellow at Stanford University discussed implications of his institution’s findings on treatment-related secondary malignancies.

Among the 5 patients in the efficacy set, 4 patients ceased receiving their previous standard of care therapy.

For World Cancer Day, held annually on February 4, take a look at the stories that have stood out in oncology cell therapy in recent months.

The IND clearance constitutes the first for a xenokidney product.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Barry J Byrne, MD, PhD, the chief medical advisor of MDA, also shared his thoughts on the 75th anniversary of the organization.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

In Episode 1 of ImmunoLogic, Stephen J. Schuster, MD, discussed the potential of treating lymphoma without chemotherapy.

Barry J Byrne, MD, PhD, the chief medical advisor of MDA, discussed what attendees can expect at the 2025 MDA Meeting.

The company received a recommendation from the study’s IDMC to move onto enrollment for the trial’s second cohort.

The chief medical advisor of the Muscular Dystrophy Association also shared his thoughts on the 75th anniversary of the organization.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

With regard to safety, the company stated that no new safety signals have been reported.

The chief medical advisor of the Muscular Dystrophy Association discussed what attendees can expect at the 2025 MDA Meeting.

The planned phase 1 RESOLUTION study will include patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.

Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program at UCLA, discussed initial data from a phase 1/2 trial.

The company has begun the process of randomly assigning enrolled participants in the sham-controlled phase 2 REGENERATE-PD trial.

We've compiled a list of 5 clinical trials with expected data readouts in 2025 that are worth keeping an eye on.

David Porter, MD, the director of cell therapy and transplant at Penn Medicine, also summed up his main message regarding the current state of the field in general.

Review top news and interview highlights from the week ending January 24, 2025.

The medical director of the Immune Effector Cell Therapy Program at UCLA discussed initial data from a phase 1/2 trial.

The company stated it expects to submit a BLA to the FDA next year.

The director of cell therapy and transplant at Penn Medicine also summed up his main message regarding the current state of the field in general.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

At 12 months of follow-up, there were no dose-limiting toxicities and no severe adverse events related to the treatment reported.

David Porter, MD, the director of cell therapy and transplant at Penn Medicine, discussed progress made and experienced gained for the field of cell therapy in autoimmune disease in 2024.